Details of the Drug
General Information of Drug (ID: DM2UFXE)
Drug Name |
1-benzyl-1H-indole-2,3-dione
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1-Benzyl-1H-indole-2,3-dione; 1217-89-6; 1-benzylisatin; 1-benzylindole-2,3-dione; 1-benzyl-2,3-dihydro-1H-indole-2,3-dione; 1-benzylindoline-2,3-dione; 1-Benzyl-2,3-indolinedione; 1H-indole-2,3-dione, 1-(phenylmethyl)-; 1H-Indole-2,3-dione,1-(phenylmethyl)-; benzylisatin; N-benzylisatin; N-benzyl isatin; 4kwf; NSC100000; AC1Q6FLI; AC1Q6FLG; AC1L6CGC; Isatin-based compound, 14; AC1Q6K6Z; N1-benzyl-indole-2,3-dione; CHEMBL115581; SCHEMBL2087729; BDBM22794; CTK4B2748; DTXSID30295164; SIISFRLGYDVIRG-UHFFFAOYSA-N; MolPort-000-322-417
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 237.25 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.1 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 0 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||